Molecular tumor board availability and organization in sarcoma referral centers in Italy: are we on the right track? - Poll - MDSpire

Molecular tumor board availability and organization in sarcoma referral centers in Italy: are we on the right track?

  • By

  • Concetta Elisa Onesti

  • Beatrice Casini

  • Annarosaria De Chiara

  • Valentina Fausti

  • Roberto Luksch

  • Giuseppe Maria Milano

  • Emanuela Palmerini

  • Sabrina Vari

  • Serena Ceddia

  • Federica Riva

  • Toni Ibrahim

  • Renato Covello

  • Gennaro Ciliberto

  • Katia Scotlandi

  • Virginia Ferraresi

  • June 3, 2026

  • 0 min

Share

Original Source(s)

Molecular tumor board availability and organization in sarcoma referral centers in Italy: are we on the right track?

  • by Concetta Elisa Onesti, Beatrice Casini, Annarosaria De Chiara, Valentina Fausti, Roberto Luksch, Giuseppe Maria Milano, Emanuela Palmerini, Sabrina Vari, Serena Ceddia, Federica Riva, Toni Ibrahim, Renato Covello, Gennaro Ciliberto, Katia Scotlandi, Virginia Ferraresi

  • June 3, 2026

Related Content

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

  • June 1, 2026

  • 5 min
A case report of thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with literature review

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis